Loading...

AQST AQUESTIVE THERAPEUTICS INC US FDA Inspections 8-K Filing

QSTV

QST

AQUESTIVE THERAPEUTICS INC

(AQST)

2024 8-K

Investor Presentation Update

Q3 Financial Update

Patent Issuance

Investor Presentation Update

Investor Presentation

FDA Advisory Update

Stock Offering Announcement

Purchase Agreement

Product Expansion

New Product Launches

Financial Statements

Pediatric Study Results

Investor Presentation

Financial Results

Presentation Announcement

Financial Update

FDA Approval News

Board Resignation

Investor Presentation

Q3 Earnings Report

Product Presentation

Positive Study Results

Bylaw Amendments

Investor Day Announcement

Investor Presentations

Financial Results Announcement

Positive PK data for Anaphy...

Annual Meeting Voting Results

Disclosure of Information

Promotion of Cassie Jung to...

Disclosure of Investor Pres...

Financial Results Announcement

FDA Approval and Clinical D...

Appointment of Director

Public Offering

Clinical Data and FDA Meeting

Financial Results Announcement

Sales Plan Adoption

Phase 3 Clinical Study Init...

Disclosure of Investor Pres...

Financial Results and Busin...

Purchase Agreements and Red...

Business Update

Disclosure of Investor Pres...

Financial Results Announcement

Securities Purchase Agreements

Product Trial Results

Investor Conferences

Annual Meeting Voting Results

Financial Results Announcement

Compliance regained with Na...

Regulation FD Disclosure

Disclosure of Investor Pres...

Financial Results Announcement

Amendment to Commercial Exp...

Bylaws Amendment

External Links:

Aquestive Therapeutics announced positive feedback from the FDA regarding its upcoming New Drug Application for Anaphylm (epinephrine) Sublingual Film, expected to be submitted in Q1 2025, and plans to present supplemental materials to investors.

AI Assistant

AQUESTIVE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.